AU Stock MarketDetailed Quotes
TYP Tryptamine Therapeutics Ltd
- 0.044
- +0.004+10.00%
20min DelayTrading Dec 4 13:44 AET
56.16MMarket Cap-483P/E (Static)
0.045High0.042Low2.09MVolume0.042Open0.040Pre Close91.31KTurnover0.05752wk High0.26%Turnover Ratio1.28BShares0.01752wk Low-0.038EPS TTM35.45MFloat Cap0.057Historical HighLossP/E (Static)805.64MShs Float0.017Historical Low-0.091EPS LYR7.50%Amplitude--Dividend TTM11.00P/B1Lot Size--Div YieldTTM
About Tryptamine Therapeutics Ltd Company
Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).
Company Profile
SymbolTYP
Company NameTryptamine Therapeutics Ltd
Founded2013
MarketASX
Employees50
Fiscal Year Ends06-30
AddressC/o Bio101 Financial Advisory Pty Ltd 697 Burke Road, Suite 201
CityMelbourne
CountryAustralia
Zip Code3124
Phone+61 390920475
Share RegistryAUTOMIC REGISTRY SERVICES
Level 5, 126 Phillip Street, SYDNEY, NSW, AUSTRALIA, 2000
02 9698 5414
Company Executives
- Name
- Position
- Salary
- Peter Molloy
- Chief Business Officer and Executive Director,Non-Executive Director
- --
- Mark Davies
- Non-Executive Chairman,Non-Executive Director
- --
- Jason Carroll
- Non-Executive Director
- --
- Gage Jull
- Non-Executive Director
- --
- Clarke Barlow
- Non-Executive Director
- --
- Christopher Ntoumenopoulos
- Non-Executive Director
- --
Heat List
AU
Overall
Symbol
Latest Price
% Chg
No Data